WHILE YOUR PATIENTS’ SLEEVES ARE UP, SPEAK UP ABOUT COADMINISTRATION

Concomitant administration of SHINGRIX with certain other adult vaccines.

According to the CDC, recombinant and adjuvanted vaccines (like SHINGRIX) can be administered concomitantly at different anatomic sites with other adult vaccines. This includes COVID-19 vaccines.1

See CDC routine recommendations for SHINGRIX.

The Prescribing Information for SHINGRIX contains information regarding the concomitant administration of SHINGRIX with flu, pneumococcal, and Tdap vaccines.2

Data are limited regarding the coadministration of SHINGRIX with other vaccines.

Results from open label studies of adults ≥50 years old who received SHINGRIX concomitantly administered with another vaccine2

FLUARIX QUADRIVALENT
(Influenza Vaccine)*		 PNEUMOVAX 23
(Pneumococcal Vaccine Polyvalent)		 BOOSTRIX
(Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)		 PREVNAR 13
(Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

Study design

  • Co-ad group: 1 dose each of SHINGRIX and FLUARIX QIV at Month 0 and 1 dose of SHINGRIX at Month 2 (n=413)
  • Sequential group: 1 dose of FLUARIX QIV at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=415)
  • Co-ad group: 1 dose each of SHINGRIX and PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Month 2 (n=432)
  • Sequential group: 1 dose of PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=433)
  • Co-ad group: 1 dose each of SHINGRIX and BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Month 2 (n=412)
  • Sequential group: 1 dose of BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=418)
  • Co-ad group: 1 dose each of SHINGRIX and PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Month 2 (n=449)
  • Sequential group: 1 dose of PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=463)

Key findings

No evidence for interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine

*Data for FLUARIX QUADRIVALENT, referenced here, are relevant to FLUARIX (Influenza Vaccine) because both vaccines are manufactured using the same process and have overlapping compositions.
  • When PNEUMOVAX 23 was coadministered with the first dose of SHINGRIX, compared with when the first dose of SHINGRIX was given alone, a greater percentage of subjects reported fever, defined as ≥37.5°C/99.5°F (16% vs 7%, respectively) and shivering (21% vs 7%, respectively) within 7 days post-vaccination
  • No evidence for interference in the immune response to the antigen contained in SHINGRIX or to the 12 evaluated antigens contained in PNEUMOVAX 23 when the two vaccines were administered concomitantly.
  • Concomitant administration showed no evidence for interference in the immune response to the antigen contained in SHINGRIX or the antigens contained in BOOSTRIX, with the exception of one of the pertussis antigens (pertactin)†
  • The clinical significance of the reduced immune response to pertactin is unknown

†The noninferiority criterion for pertactin was not met as the UL of the 95% CI for the adjusted GMC ratio (sequential administration group/concomitant administration group) for anti-pertactin antibody was 1.58 (noninferiority criterion <1.5).

No evidence for interference in the immune response to the antigens contained in SHINGRIX or PREVNAR 13 when the two vaccines were administered concomitantly

Results from open label studies of adults ≥50 years old who received SHINGRIX concomitantly administered with another vaccine2

FLUARIX QUADRIVALENT
(Influenza Vaccine)*

Study design

  • Co-ad group: 1 dose each of SHINGRIX and FLUARIX QIV at Month 0 and 1 dose of SHINGRIX at Month 2 (n=413)
  • Sequential group: 1 dose of FLUARIX QIV at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=415)

Key findings

No evidence for interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine

*Data for FLUARIX QUADRIVALENT, referenced here, are relevant to FLUARIX (Influenza Vaccine) because both vaccines are manufactured using the same process and have overlapping compositions.
PNEUMOVAX 23
(Pneumococcal Vaccine Polyvalent)

Study design

  • Co-ad group: 1 dose each of SHINGRIX and PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Month 2 (n=432)
  • Sequential group: 1 dose of PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=433)

Key findings

  • When PNEUMOVAX 23 was coadministered with the first dose of SHINGRIX, compared with when the first dose of SHINGRIX was given alone, a greater percentage of subjects reported fever, defined as ≥37.5°C/99.5°F (16% vs 7%, respectively) and shivering (21% vs 7%, respectively) within 7 days post-vaccination
  • No evidence for interference in the immune response to the antigen contained in SHINGRIX or to the 12 evaluated antigens contained in PNEUMOVAX 23 when the two vaccines were administered concomitantly.
BOOSTRIX
(Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)

Study design

  • Co-ad group: 1 dose each of SHINGRIX and BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Month 2 (n=412)
  • Sequential group: 1 dose of BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=418)

Key findings

  • Concomitant administration showed no evidence for interference in the immune response to the antigen contained in SHINGRIX or the antigens contained in BOOSTRIX, with the exception of one of the pertussis antigens (pertactin)†
  • The clinical significance of the reduced immune response to pertactin is unknown

†The noninferiority criterion for pertactin was not met as the UL of the 95% CI for the adjusted GMC ratio (sequential administration group/concomitant administration group) for anti-pertactin antibody was 1.58 (noninferiority criterion <1.5).
PREVNAR 13
(Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

Study design

  • Co-ad group: 1 dose each of SHINGRIX and PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Month 2 (n=449)
  • Sequential group: 1 dose of PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=463)

Key findings

No evidence for interference in the immune response to the antigens contained in SHINGRIX or PREVNAR 13 when the two vaccines were administered concomitantly

CDC=Centers for Disease Control and Prevention; CI=confidence interval; COVID-19=coronavirus disease 2019; GMC=geometric mean concentration; Tdap=tetanus, diphtheria, and acellular pertussis. 

Now is the time to consider coadministration of SHINGRIX with other adult vaccines.

Administer or schedule an appointment at ScheduleSHINGRIX.com

SHINGRIX Coadministration Leave Behind

Coadministration Guide

DOWNLOAD RESOURCES
Download PDF Root Path

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. SHINGRIX recommendations. Centers for Disease Control and Prevention. Reviewed January 24, 2022. Accessed August 9, 2024. https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html 

  2. Prescribing Information for SHINGRIX.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET